Who are Lansoprazole/Domperidone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): omeprazole+domperidone SR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lansoprazole-domperidone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lansoprazole/Domperidone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lansoprazole/Domperidone (Lansoprazole/Domperidone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + dopamine antagonist combination. Area: Gastroenterology.

marketed Proton pump inhibitor + dopamine antagonist combination H+/K+-ATPase (lansoprazole); dopamine D2/D3 receptors (domperidone) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Lansoprazole/Domperidone (Lansoprazole/Domperidone) — Neutec Ar-Ge San ve Tic A.Ş. Lansoprazole reduces stomach acid by inhibiting the proton pump, while domperidone enhances gastric motility and prevents nausea by blocking dopamine receptors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lansoprazole/Domperidone TARGET	Lansoprazole/Domperidone	Neutec Ar-Ge San ve Tic A.Ş	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (lansoprazole); dopamine D2/D3 receptors (domperidone)
omeprazole+domperidone SR	omeprazole+domperidone SR	Belarusian Medical Academy of Post-Graduate Education	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (omeprazole); dopamine D2/D3 receptors (domperidone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + dopamine antagonist combination class)

Belarusian Medical Academy of Post-Graduate Education · 1 drug in this class
Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lansoprazole/Domperidone — Competitive Intelligence Brief. https://druglandscape.com/ci/lansoprazole-domperidone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab